Skip to content
MARKETS / NASDAQ / DRIO
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

DarioHealth Corp. DRIO

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$22.4M
▼ 17.3% YoY
$-41.7M
$-26.1M
Growth
USD 22.4M
Revenue, FY2025 · full 14-year series below
Revenue $M Net income $M
FY2025 · Revenue 22.4 · Net income -41.7
10M20M-40M20122014201620182020202220242025
Compound annual growth
−6.8%
+24.2%
+39.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +24.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−187 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -163.9% · Net -186.6%
-10000%-20000%20122014201620182020202220242025
ROE
FY2025 · ROE -59.6%
-100%-200%20122014201620182020202220242025

Each USD of equity lost 60 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -26.1
-20M-40M20122014201620182020202220242025
Net buybacks $M Dividends $M
FY2022 · Dividends — · Net buybacks -38.2
-20M2022

Total assetsUSD 110.1M
EquityUSD 67.9M
CashUSD 21.8M
Gross debtUSD 30.7M
Net debtUSD 8.9M
Current ratio3.76×

Net debt stands at 13% of equity.

The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.0·
Operating income $B−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.0−0.00.00.00.0·········
Net income $B−0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $10.1212.271.932.544.074.018.0015.631.642.093.841.853.800.46
Dividend / sh $··············
Payout %··············
ROE %−59.6−65.7−86.0−75.1−135.0−125.2−127.5−276.7······
Shares out B0.010.000.030.030.020.010.000.000.010.010.000.020.000.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 9 failures · 2 divergences in 69 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 26 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente9 failures2 divergent
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image